{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:24:26Z","timestamp":1791051866630,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79888-w","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T10:10:44Z","timestamp":1731924644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing screening rates for bone health management in prostate cancer patients on androgen deprivation therapy with an automated outpatient system"],"prefix":"10.1038","volume":"14","author":[{"given":"Chun-Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shian-Shiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Shu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Che","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Kuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ri","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Yuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"79888_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. Cancer statistics CA: A Cancer J. Clin. 71, 7\u201333, https:\/\/doi.org\/10.3322\/caac.21654 (2021).","DOI":"10.3322\/caac.21654"},{"key":"79888_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","volume":"70","author":"MY Teo","year":"2019","unstructured":"Teo, M. Y., Rathkopf, D. E. & Kantoff, P. Treatment of advanced prostate Cancer. Annu. Rev. Med. 70, 479\u2013499. https:\/\/doi.org\/10.1146\/annurev-med-051517-011947 (2019).","journal-title":"Annu. Rev. Med."},{"key":"79888_CR3","doi-asserted-by":"publisher","unstructured":"Sekhoacha, M. et al. Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches. Molecules. 27 https:\/\/doi.org\/10.3390\/molecules27175730 (2022).","DOI":"10.3390\/molecules27175730"},{"key":"79888_CR4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/bonekey.2015.85","volume":"4","author":"M Bienz","year":"2015","unstructured":"Bienz, M. & Saad, F. Androgen-deprivation therapy and bone loss in prostate cancer patients: A clinical review. Bonekey Rep. 4, 716. https:\/\/doi.org\/10.1038\/bonekey.2015.85 (2015).","journal-title":"Bonekey Rep."},{"key":"79888_CR5","doi-asserted-by":"publisher","unstructured":"Kim, T. J. & Koo, K. C. Pathophysiology of bone loss in patients with prostate Cancer receiving androgen-deprivation therapy and lifestyle modifications for the management of Bone Health: a Comprehensive Review. Cancers (Basel). 12. https:\/\/doi.org\/10.3390\/cancers12061529 (2020).","DOI":"10.3390\/cancers12061529"},{"key":"79888_CR6","doi-asserted-by":"publisher","first-page":"e930839","DOI":"10.12659\/msm.930839","volume":"27","author":"P Sawicki","year":"2021","unstructured":"Sawicki, P., Ta\u0142a\u0142aj, M., \u017byci\u0144ska, K., Zgliczy\u0144ski, W. S. & Wierzba, W. Current applications and selected technical details of dual-energy X-ray absorptiometry. Med. Sci. Monit. 27, e930839. https:\/\/doi.org\/10.12659\/msm.930839 (2021).","journal-title":"Med. Sci. Monit."},{"key":"79888_CR7","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/s0022-5347(05)64561-2","volume":"168","author":"MG Oefelein","year":"2002","unstructured":"Oefelein, M. G., Ricchiuti, V., Conrad, W. & Resnick, M. I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168, 1005\u20131007. https:\/\/doi.org\/10.1016\/s0022-5347(05)64561-2 (2002).","journal-title":"J. Urol."},{"key":"79888_CR8","doi-asserted-by":"publisher","unstructured":"Baldessari, C. et al. Bone metastases and health in prostate cancer: From pathophysiology to clinical implications. Cancers (Basel). 15 https:\/\/doi.org\/10.3390\/cancers15051518 (2023).","DOI":"10.3390\/cancers15051518"},{"key":"79888_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer, E. M. et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 21, 1067\u20131096. https:\/\/doi.org\/10.6004\/jnccn.2023.0050 (2023).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"79888_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker, C. et al. Prostate cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Annals Oncol.: Off. J. Eur. Soc. Med. Oncol. 31, 1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011 (2020).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"key":"79888_CR11","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.6004\/jnccn.2020.7576","volume":"18","author":"J Hu","year":"2020","unstructured":"Hu, J., Aprikian, A. G., Vanhuyse, M. & Dragomir, A. Contemporary Population-based analysis of bone mineral density testing in men initiating androgen deprivation therapy for prostate Cancer. J. Natl. Compr. Canc Netw. 18, 1374\u20131381. https:\/\/doi.org\/10.6004\/jnccn.2020.7576 (2020).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"79888_CR12","doi-asserted-by":"publisher","first-page":"e225432","DOI":"10.1001\/jamanetworkopen.2022.5432","volume":"5","author":"ME Suarez-Almazor","year":"2022","unstructured":"Suarez-Almazor, M. E. et al. Association of Bone Mineral Density Testing with Risk of Major Osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or Regional prostate Cancer. JAMA Netw. Open. 5, e225432. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.5432 (2022).","journal-title":"JAMA Netw. Open."},{"key":"79888_CR13","doi-asserted-by":"publisher","first-page":"101750","DOI":"10.1016\/j.bonr.2024.101750","volume":"20","author":"AE Smit","year":"2024","unstructured":"Smit, A. E., Meijer, O. C. & Winter, E. M. The multi-faceted nature of age-associated osteoporosis. Bone Rep. 20, 101750. https:\/\/doi.org\/10.1016\/j.bonr.2024.101750 (2024).","journal-title":"Bone Rep."},{"key":"79888_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5489\/cuaj.12149","volume":"6","author":"A So","year":"2012","unstructured":"So, A., Chin, J., Fleshner, N. & Saad, F. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can. Urol. Assoc. J. 6, 465\u2013470. https:\/\/doi.org\/10.5489\/cuaj.12149 (2012).","journal-title":"Can. Urol. Assoc. J."},{"key":"79888_CR15","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/s0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 387, 1163\u20131177. https:\/\/doi.org\/10.1016\/s0140-6736(15)01037-5 (2016).","journal-title":"Lancet"},{"key":"79888_CR16","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1200\/jco.2013.51.6500","volume":"32","author":"MR Smith","year":"2014","unstructured":"Smith, M. R. et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J. Clin. Oncol. Offi. J. Am. Soc. Clin. Oncol. 32, 1143\u20131150. https:\/\/doi.org\/10.1200\/jco.2013.51.6500 (2014).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"79888_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1200\/op.23.00602","volume":"20","author":"AP Mitchell","year":"2024","unstructured":"Mitchell, A. P. et al. Costs to Medicare of Nonrecommended Bone-Modifying Agent use for castration-sensitive prostate Cancer. JCO Oncol. Pract. 20, 393\u2013400. https:\/\/doi.org\/10.1200\/op.23.00602 (2024).","journal-title":"JCO Oncol. Pract."},{"key":"79888_CR18","doi-asserted-by":"publisher","first-page":"e242467","DOI":"10.1001\/jamanetworkopen.2024.2467","volume":"7","author":"W Fukuokaya","year":"2024","unstructured":"Fukuokaya, W. et al. Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate Cancer treated with abiraterone acetate. JAMA Netw. Open. 7, e242467. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.2467 (2024).","journal-title":"JAMA Netw. Open."},{"key":"79888_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/OP.2023.19.11_suppl.12","volume":"19","author":"AP Mitchell","year":"2023","unstructured":"Mitchell, A. P. et al. Cost to Medicare from bone modifying agent overuse in castration-sensitive prostate cancer. JCO Oncol. Pract. 19, 12\u201312. https:\/\/doi.org\/10.1200\/OP.2023.19.11_suppl.12 (2023).","journal-title":"JCO Oncol. Pract."},{"key":"79888_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jnci\/djab196","volume":"114","author":"AP Mitchell","year":"2022","unstructured":"Mitchell, A. P. et al. Real-world use of bone-modifying agents in metastatic castration-sensitive prostate Cancer. J. Natl. Cancer Inst. 114, 419\u2013426. https:\/\/doi.org\/10.1093\/jnci\/djab196 (2022).","journal-title":"J. Natl. Cancer Inst."},{"key":"79888_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21681805.2019.1570328","volume":"53","author":"MH Poulsen","year":"2019","unstructured":"Poulsen, M. H. et al. Osteoporosis and prostate cancer; a 24-month prospective observational study during androgen deprivation therapy. Scand. J. Urol. 53, 34\u201339. https:\/\/doi.org\/10.1080\/21681805.2019.1570328 (2019).","journal-title":"Scand. J. Urol."},{"key":"79888_CR22","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1590\/1413-81232023287.10602022","volume":"28","author":"EM Ribeiro","year":"2023","unstructured":"Ribeiro, E. M. et al. Bone health education programs for older people: An integrative review. Cien Saude Colet. 28, 2025\u20132034. https:\/\/doi.org\/10.1590\/1413-81232023287.10602022 (2023).","journal-title":"Cien Saude Colet"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79888-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79888-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T02:13:20Z","timestamp":1732241600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79888-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79888"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79888-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28460"}}